"The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a form of cancer located in the region where the esophagus joins the stomach./"...
Doses of Neumega (oprelvekin) above 125 µg/kg have not been administered to humans. While clinicalexperience is limited, doses of Neumega (oprelvekin) greater than 50 µg/kg may be associated with anincreased incidence of cardiovascular events in adult patients (see WARNINGS, Fluid Retention and Cardiovascular Events). If an overdose of Neumega (oprelvekin) is administered, Neumega (oprelvekin) should be discontinued, and the patient should be closely observed for signs of toxicity (see WARNINGS and ADVERSE REACTIONS). Reinstitution of Neumega (oprelvekin) therapy should be based upon individual patient factors (eg, evidence of toxicity, continued need for therapy).
Neumega (oprelvekin) is contraindicated in patients with a history of hypersensitivity to Neumega (oprelvekin) or any component of the product (see WARNINGS, Allergic Reactions Including Anaphylaxis).
Last reviewed on RxList: 10/21/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Neumega Information
Neumega - User Reviews
Neumega User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.